Literature DB >> 9590442

Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat.

C Zhang1, R Raghupathi, K E Saatman, D H Smith, J M Stutzmann, F Wahl, T K McIntosh.   

Abstract

The neuroprotective effects of Riluzole, a compound with several mechanisms of action including the inhibition of sodium channel activity and glutamate release, were evaluated in a rat model of parasagittal fluid-percussion (FP) brain injury. Male Sprague-Dawley rats (350-400 g, n = 17) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and subjected to parasagittal FP brain injury of moderate severity (2.3-2.5 atm). Fifteen min following injury, animals randomly received an i.v. bolus of either Riluzole (8 mg/kg, n = 8) or vehicle (n = 9), followed by subcutaneous injections (identical dose) at 6 hr and 24 hr. Two weeks after injury and drug treatment, animals were sacrificed and a series of brain sections, stained with Hematoxylin and Eosin (H&E) or cresyl violet, were evaluated for quantitative cortical lesion volume and cell counts of hippocampal CA3 neurons, respectively, using a computerized image analysis system. Administration of Riluzole significantly reduced FP-induced tissue loss in the temporal/occipital cortices ipsilateral to the site of impact by 46%, compared to vehicle-treated, brain-injured animals (P = 0.01). In contrast, the selective neuronal loss observed in the CA3 region of the ipsilateral hippocampus was unaffected by Riluzole treatment. The present study demonstrates that Riluzole can attenuate cortical lesion size following brain trauma. These neuroprotective effects may be related to the synergy of the different mechanisms of action of Riluzole.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9590442     DOI: 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  21 in total

Review 1.  A review of neuroprotection pharmacology and therapies in patients with acute traumatic brain injury.

Authors:  Kevin W McConeghy; Jimmi Hatton; Lindsey Hughes; Aaron M Cook
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Post-trauma administration of the pifithrin-α oxygen analog improves histological and functional outcomes after experimental traumatic brain injury.

Authors:  L-Y Yang; Y-H Chu; D Tweedie; Q-S Yu; C G Pick; B J Hoffer; N H Greig; J-Y Wang
Journal:  Exp Neurol       Date:  2015-03-24       Impact factor: 5.330

3.  Genetic deletion and pharmacological inhibition of Nogo-66 receptor impairs cognitive outcome after traumatic brain injury in mice.

Authors:  Anders Hånell; Fredrik Clausen; Maria Björk; Kristine Jansson; Ola Philipson; Lars N G Nilsson; Lars Hillered; Paul H Weinreb; Daniel Lee; Tracy K McIntosh; David A Gimbel; Stephen M Strittmatter; Niklas Marklund
Journal:  J Neurotrauma       Date:  2010-07       Impact factor: 5.269

4.  Blockage of the upregulation of voltage-gated sodium channel nav1.3 improves outcomes after experimental traumatic brain injury.

Authors:  Xian-Jian Huang; Wei-Ping Li; Yong Lin; Jun-Feng Feng; Feng Jia; Qing Mao; Ji-Yao Jiang
Journal:  J Neurotrauma       Date:  2013-12-06       Impact factor: 5.269

Review 5.  Glutamate receptors, neurotoxicity and neurodegeneration.

Authors:  Anthony Lau; Michael Tymianski
Journal:  Pflugers Arch       Date:  2010-03-14       Impact factor: 3.657

6.  Acute, transient hemorrhagic hypotension does not aggravate structural damage or neurologic motor deficits but delays the long-term cognitive recovery following mild to moderate traumatic brain injury.

Authors:  Christian Schütz; John F Stover; Hilaire J Thompson; Rachel C Hoover; Diego M Morales; Joost W Schouten; Asenia McMillan; Kristie Soltesz; Melissa Motta; Zachery Spangler; Edmund Neugebauer; Tracy K McIntosh
Journal:  Crit Care Med       Date:  2006-02       Impact factor: 7.598

7.  Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody.

Authors:  Hilaire J Thompson; Niklas Marklund; David G LeBold; Diego M Morales; Carrie A Keck; Mary Vinson; Nicolas C Royo; Robert Grundy; Tracy K McIntosh
Journal:  Eur J Neurosci       Date:  2006-12       Impact factor: 3.386

Review 8.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

9.  The novel antiepileptic agent RWJ-333369-A, but not its analog RWJ-333369, reduces regional cerebral edema without affecting neurobehavioral outcome or cell death following experimental traumatic brain injury.

Authors:  Carrie A Keck; Hilaire J Thompson; Asla Pitkänen; David G LeBold; Diego M Morales; Jamie B Plevy; Rishi Puri; Boyu Zhao; Marc Dichter; Tracy K McIntosh
Journal:  Restor Neurol Neurosci       Date:  2007       Impact factor: 2.406

Review 10.  Glutamate Neurotransmission in Rodent Models of Traumatic Brain Injury.

Authors:  Christopher R Dorsett; Jennifer L McGuire; Erica A K DePasquale; Amanda E Gardner; Candace L Floyd; Robert E McCullumsmith
Journal:  J Neurotrauma       Date:  2016-07-06       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.